BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+27.77%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$8.73B
AUM Growth
+$8.73B
(+21%)
Cap. Flow
+$239M
Cap. Flow
% of AUM
2.73%
Top 10 Holdings %
Top 10 Hldgs %
31.85%
Holding
234
New
17
Increased
81
Reduced
66
Closed
12
Top Buys
| 1 |
Biogen
BIIB
|
$136M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$65.8M |
| 3 |
Mersana Therapeutics
MRSN
|
$51.3M |
| 4 |
Arvinas
ARVN
|
$46.7M |
| 5 |
AbbVie
ABBV
|
$36.3M |
Top Sells
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$154M |
| 2 |
Halozyme
HALO
|
$60.8M |
| 3 |
Pacific Biosciences
PACB
|
$57.2M |
| 4 |
CareDx
CDNA
|
$55.9M |
| 5 |
Charles River Laboratories
CRL
|
$52M |
Sector Composition
| 1 | Healthcare | 95.9% |
| 2 | Technology | 0.6% |
| 3 | Industrials | 0.33% |
| 4 | Financials | 0.11% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Insmed
INSM
$30.3B
| $53.8M | 0.62% |
1,617,000
+396,831
| +33% | +$13.2M |
|
|
52
Mersana Therapeutics
MRSN
$34.8M
| $51.3M | 0.59% |
+1,926,010
| New | +$51.3M |
|
53
Evolent Health
EVH
$1.11B
| $50.5M | 0.58% |
3,149,111
-124,214
| -4% | -$1.99M |
|
54
Amgen
AMGN
$153B
| $50.1M | 0.57% |
217,990
+38,377
| +21% | +$8.82M |
|
55
Teleflex
TFX
$5.57B
| $48.5M | 0.56% |
117,778
+39,134
| +50% | +$16.1M |
|
56
Black Diamond Therapeutics
BDTX
$164M
| $45M | 0.52% |
1,403,000
| – | – |
|
|
SWAV
57
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $44.1M | 0.51% |
425,335
-35,918
| -8% | -$3.73M |
|
|
58
Pacific Biosciences
PACB
$378M
| $44.1M | 0.5% |
1,698,179
-2,206,288
| -57% | -$57.2M |
|
59
Molina Healthcare
MOH
$9.6B
| $42.5M | 0.49% |
199,688
+35,116
| +21% | +$7.47M |
|
60
Teladoc Health
TDOC
$1.37B
| $42.1M | 0.48% |
210,352
+88,998
| +73% | +$17.8M |
|
61
DaVita
DVA
$9.72B
| $41.5M | 0.47% |
353,200
+26,800
| +8% | +$3.15M |
|
|
62
AbbVie
ABBV
$374B
| $40.2M | 0.46% |
375,500
+338,500
| +915% | +$36.3M |
|
63
Idexx Laboratories
IDXX
$50.7B
| $39M | 0.45% |
78,085
-313
| -0.4% | -$156K |
|
64
Globus Medical
GMED
$7.94B
| $38.1M | 0.44% |
584,612
+174,877
| +43% | +$11.4M |
|
65
Baxter International
BAX
$12.1B
| $38.1M | 0.44% |
474,623
| – | – |
|
|
GNMK
66
DELISTED
GenMark Diagnostics, Inc
GNMK
| $38.1M | 0.44% |
2,606,636
+1,342,825
| +106% | +$19.6M |
|
67
Zimmer Biomet
ZBH
$20.8B
| $37.7M | 0.43% |
244,761
+19,021
| +8% | +$2.93M |
|
68
Bio-Rad Laboratories Class A
BIO
$7.8B
| $37.5M | 0.43% |
64,405
-13,781
| -18% | -$8.03M |
|
69
Tandem Diabetes Care
TNDM
$834M
| $36.9M | 0.42% |
385,184
+71,740
| +23% | +$6.86M |
|
|
70
Charles River Laboratories
CRL
$7.99B
| $35.7M | 0.41% |
143,018
-208,065
| -59% | -$52M |
|
71
Omnicell
OMCL
$1.51B
| $35.6M | 0.41% |
296,303
+17,882
| +6% | +$2.15M |
|
|
ABMD
72
DELISTED
Abiomed Inc
ABMD
| $34.9M | 0.4% |
107,557
+6,159
| +6% | +$2M |
|
73
Glaukos
GKOS
$5.42B
| $33.8M | 0.39% |
449,332
-66,422
| -13% | -$5M |
|
|
CHNG
74
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $33.3M | 0.38% |
1,785,974
+88,035
| +5% | +$1.64M |
|
75
Quanterix
QTRX
$202M
| $33.2M | 0.38% |
712,999
-10,675
| -1% | -$496K |
|